Anti-vascular endothelial growth factor for neovascular glaucoma.

CONCLUSIONS: Currently available evidence is uncertain regarding the long-term effectiveness of anti-VEGF medications, such as intravitreal ranibizumab or bevacizumab or aflibercept, as an adjunct to conventional treatment in lowering IOP in NVG. More research is needed to investigate the long-term effect of these medications compared with, or in addition to, conventional surgical or medical treatment in lowering IOP in NVG. PMID: 32027392 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32027392?dopt=Abstract

Source: Cochrane Database of Systematic Reviews - February 5, 2020 Category: General Medicine Authors: Simha A, Aziz K, Braganza A, Abraham L, Samuel P, Lindsley KB Tags: Cochrane Database Syst Rev Source Type: research